These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 19473660

  • 1. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
    Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
    [Abstract] [Full Text] [Related]

  • 2. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
    Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
    [Abstract] [Full Text] [Related]

  • 3. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Jun; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 4. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
    [Abstract] [Full Text] [Related]

  • 5. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
    Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K.
    Arthritis Res Ther; 2013 Dec; 15(3):R69. PubMed ID: 23800379
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
    Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ, Kaminski KA.
    Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
    [Abstract] [Full Text] [Related]

  • 7. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
    Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA.
    Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
    [Abstract] [Full Text] [Related]

  • 8. CD163+ macrophages are associated with a vulnerable plaque phenotype in human carotid plaques.
    Bengtsson E, Hultman K, Edsfeldt A, Persson A, Nitulescu M, Nilsson J, Gonçalves I, Björkbacka H.
    Sci Rep; 2020 Sep 01; 10(1):14362. PubMed ID: 32873809
    [Abstract] [Full Text] [Related]

  • 9. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG.
    Int Urol Nephrol; 2015 Dec 01; 47(12):2023-30. PubMed ID: 26433887
    [Abstract] [Full Text] [Related]

  • 10. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.
    Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.
    J Immunol; 2007 Jun 15; 178(12):8183-94. PubMed ID: 17548657
    [Abstract] [Full Text] [Related]

  • 11. Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.
    Dirajlal-Fargo S, Sattar A, Kulkarni M, Funderburg N, McComsey GA.
    HIV Clin Trials; 2017 Jul 15; 18(4):156-163. PubMed ID: 28828963
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
    Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR.
    PLoS One; 2012 Jul 15; 7(8):e43919. PubMed ID: 22937125
    [Abstract] [Full Text] [Related]

  • 13. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
    Peng S, Yu X, Zhao X, Wang X, Sun X, Han C, Shan Z, Li C, Teng W.
    Clin Endocrinol (Oxf); 2017 Dec 15; 87(6):783-790. PubMed ID: 28636775
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis.
    Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, Louedec L, Esposito-Farèse M, Tubach F, Nicoletti A, Steg PG, Michel JB, Feldman L, Meilhac O.
    Eur Heart J; 2012 Jan 15; 33(2):252-63. PubMed ID: 21606088
    [Abstract] [Full Text] [Related]

  • 15. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
    Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC.
    J Rheumatol; 2015 Jun 15; 42(6):979-87. PubMed ID: 25877505
    [Abstract] [Full Text] [Related]

  • 16. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.
    Møller HJ, Nielsen MJ, Maniecki MB, Madsen M, Moestrup SK.
    Immunobiology; 2010 May 15; 215(5):406-12. PubMed ID: 19581020
    [Abstract] [Full Text] [Related]

  • 17. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S.
    J Dermatol Sci; 2012 Oct 15; 68(1):45-51. PubMed ID: 22884782
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T.
    Arthritis Res Ther; 2017 Jan 19; 19(1):9. PubMed ID: 28103926
    [Abstract] [Full Text] [Related]

  • 19. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis.
    Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L.
    Atherosclerosis; 2006 Feb 19; 184(2):342-7. PubMed ID: 15979079
    [Abstract] [Full Text] [Related]

  • 20. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
    Fernández-Laso V, Sastre C, Valdivielso JM, Fernández E, Martín-Ventura JL, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2015 Apr 19; 239(2):358-63. PubMed ID: 25681674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.